FIELD: biotechnology.
SUBSTANCE: invention concerns biotechnology and medicine. Claimed method involves priming of immune response to malaria by DNA-based vaccine and response stimulation by protein-based vaccine. Invention claims vaccine including priming composition of at least one polynucleotide encoding at least one first anti-malaria antigen, and stimulating composition of at least one polypeptide activating additionally at least one second anti-malaria antigen. Also invention concerns human immunisation kit for malaria-inducing pathogen.
EFFECT: expanded immune response due to recurrent immunisation (stimulation) by protein-based vaccine.
44 cl, 7 ex, 12 dwg, 5 tbl
Authors
Dates
2009-05-27—Published
2003-10-22—Filed